文献速递复苏、休克与脓毒症

组蛋白去乙酰化酶抑制剂亚型选择性改善失血性休克模型生存率

Histone deacetylase inhibitors: Isoform selectivity improves survival in a hemorrhagic shock model.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论大鼠致死性失血性休克模型中,IIa或IIb类而非I类组蛋白去乙酰化酶抑制剂可改善24小时生存率并激活促存活通路。

本研究为动物实验,使用Sprague-Dawley大鼠建立致死性失血性休克(50%失血)模型,随机分为8组(每组n=8)比较不同亚型组蛋白去乙酰化酶抑制剂(HDACI)的24小时生存率。结果显示,VPA(I/IIa类)、MC1568(IIa类)、ACY1083(IIb类)分别将生存率提高至87.5%、75%、75%(p<0.05),而MS275(I类)无改善,EX527(III类)提高至50%但未达统计学显著(p=0.082)。机制研究中,VPA乙酰化组蛋白H3和H4,MC1568和ACY1083乙酰化组蛋白H4,ACY1083还乙酰化α-微管蛋白;除MS275外所有治疗组均增加磷酸化AKT和β-catenin。结论提示抑制HDAC IIa或IIb类而非I类可激活促存活通路,可能是改善失血性休克结局的机制。

要点

  • 致死性失血性休克大鼠中,VPA(I/IIa类HDACI)将24小时生存率从12.5%提高至87.5%(p<0.05)。
  • IIa类HDACI MC1568和IIb类HDACI ACY1083均将生存率提高至75%(p<0.05),而I类HDACI MS275无改善。
  • III类HDACI EX527将生存率提高至50%,但未达统计学显著(p=0.082)。
  • VPA乙酰化组蛋白H3和H4;MC1568和ACY1083乙酰化组蛋白H4;ACY1083还乙酰化α-微管蛋白。
  • 除MS275外,所有治疗组均增加磷酸化AKT和β-catenin,提示IIa/IIb类抑制激活促存活通路。

适用人群与场景

  • Sprague-Dawley大鼠致死性失血性休克模型(50%失血),用于生存研究,每组n=8。
  • Sprague-Dawley大鼠亚致死性失血性休克模型(40%失血),用于机制研究,每组n=3,排除EX527组。

处置流程与药物剂量

  • 生存研究:大鼠50%失血后随机分组,分别给予不治疗、生理盐水溶媒、环糊精溶媒、MS275(I类HDACI)、VPA(I/IIa类HDACI)、MC1568(IIa类HDACI)、ACY1083(IIb类HDACI)、EX527(III类HDACI),监测24小时生存率。
  • 机制研究:大鼠40%失血后随机分组(同生存研究但排除EX527),治疗后3小时取组织,分析心肌磷酸化AKT、β-catenin、乙酰化组蛋白H3和H4、乙酰化α-微管蛋白表达。

研究设计与关键结果

  • 研究类型:动物实验(大鼠失血性休克模型),生存研究每组n=8,机制研究每组n=3。
  • 24小时生存率:未治疗组12.5%,溶媒组和MS275组无改善,EX527组50%(p=0.082,未达统计学显著),VPA组87.5%、MC1568组75%、ACY1083组75%(p<0.05)。
  • 机制结果:VPA诱导组蛋白H3和H4乙酰化,MC1568和ACY1083增加组蛋白H4乙酰化,ACY1083还诱导α-微管蛋白乙酰化;除MS275外所有治疗组均增加磷酸化AKT和β-catenin。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:抑制HDAC IIa或IIb类而非I类可激活促存活通路,可能解释啮齿类失血性休克模型中观察到的结局改善。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemorrhage is a leading preventable cause of death. Nonselective histone deacetylase inhibitors (HDACIs), such as valproic acid (VPA), have been shown to improve outcomes in hemorrhagic shock (HS). The HDACs can be divided into four functional classes (I, IIa/IIb, III, and IV). Classes I, IIa/IIb, and III have previously been implicated in the pathophysiology of HS. This study aimed to determine which HDAC class, or classes, are responsible for the survival benefit observed with nonselective HDACIs.

METHODS: Survival study: Sprague-Dawley rats were subjected to lethal HS (50% hemorrhage) and randomized to the following groups (n = 8): (1) no treatment, (2) normal saline vehicle, (3) cyclodextrin vehicle, (4) MS275 (class I HDACI), (5) VPA (class I/IIa HDACI), (6) MC1568 (class IIa HDACI), (7) ACY1083 (class IIb HDACI), and (8) EX527 (class III HDACI). Survival was monitored for 24 hours. Mechanistic study: Sprague-Dawley rats were subjected to sublethal HS (40% hemorrhage) and randomized to the same groups (n = 3), excluding EX527, based on results of the survival study. Tissues were harvested at 3 hours posttreatment, and expression of phosphorylated-AKT, β-catenin, acetylated histones H3 and H4, and acetylated α-tubulin were analyzed in myocardial tissue.

RESULTS: Survival rate was 12.5% in the untreated group, and did not improve with vehicle or MS275 treatment. EX527 improved survival to 50%, although this did not achieve statistical significance (p = 0.082). However, treatment with VPA, MC1568, and ACY1083 improved survival rates to 87.5%, 75%, and 75%, respectively (p < 0.05). The VPA-induced acetylation of both histones H3 and H4, while MC1568 and ACY1083 increased acetylation of histone H4. ACY1083 also induced acetylation of α-tubulin. All treatment groups, except MS275, increased phosphorylated-AKT, and β-catenin.

CONCLUSION: Inhibition of HDAC classes IIa or IIb, but not class I, activates prosurvival pathways, which may be responsible for the improved outcomes in rodent models of HS.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Chang P, Weykamp M, Dennahy IS, et al. Histone deacetylase inhibitors: Isoform selectivity improves survival in a hemorrhagic shock model. J Trauma Acute Care Surg. 2018. PMID: 29401190. doi:10.1097/TA.0000000000001824

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。